Business Context and Reporting Period
Aclarion, Inc. (ACON), an emerging growth company incorporated in Delaware, filed this Form 8-K on October 1, 2024, reporting events occurring on September 30, 2024. The filing details the entry into a material definitive agreement for a $1.0 million convertible preferred stock and warrants financing.
Key Financial Metrics and Transaction Details
The Company received gross proceeds of $1,000,000 from the financing. The capital structure of the transaction includes:
- Series C Preferred Stock: 1,000 shares issued at $1,000 per share.
- Warrants: Issued for 5,685,049 shares of Common Stock with a 5.5-year term.
- Conversion/Exercise Price: Initial price set at $0.1759 per share for both the Preferred Stock and Warrants.
- Dividend Rate: 10% per annum, payable quarterly, with options to pay in Common Stock or capitalize dividends.
The filing does not provide specific data on revenue, operating profit, cash flow, margins, or existing debt levels outside of this new financing.
Material Changes and Terms
The primary material change is the issuance of new equity securities. Key terms affecting future financials include:
- Anti-Dilution Protection: Both the Preferred Stock conversion price and Warrant exercise price are subject to full ratchet adjustments if the Company issues Common Stock at a price lower than the current conversion/exercise price.
- Triggering Events: Upon specific defaults (e.g., bankruptcy, Nasdaq delisting, or breach of agreement) or if shares remain outstanding after September 30, 2026, the dividend rate increases to 18%, and the conversion price adjusts to a lower "Alternate Conversion Price."
- Redemption: The Company has the right to redeem all Series C Preferred Stock in cash at a 25% premium to the greater of the stated value or the underlying equity value.
- Liquidation Preference: Holders are entitled to 125% of the liquidation value or the conversion value, plus the Black Scholes value of the warrants, prior to Common Stockholders.
Outlook, Risks, and Contingencies
Management intends to use the proceeds for general corporate purposes. The filing highlights several risks and contingencies:
- Dilution Risk: The transaction includes significant potential dilution due to the low conversion price and the large number of warrant shares (5.68 million) relative to the capital raised.
- Registration Rights: The Company must file a registration statement within 30 days for the resale of shares underlying the Preferred Stock and Warrants.
- Ownership Limitations: Conversion and exercise are capped at 19.99% of the total Common Stock outstanding immediately prior to the agreement, unless stockholder approval is obtained.
- Unregistered Sale: Securities were sold under Section 4(a)(2) of the Securities Act and are not registered.
Investor Verification Checklist
- Verify the current number of Common Stock shares outstanding to assess the immediate dilution impact of the 5,685,049 warrant shares and the 1,000 Preferred shares.
- Review the Company's current cash position to determine the runway provided by the $1.0 million proceeds.
- Monitor the Company's ability to maintain Nasdaq listing compliance to avoid triggering the 18% dividend rate and lower conversion price.
- Check for any subsequent equity issuances that could trigger the full ratchet anti-dilution provision, further lowering the conversion price.
- Confirm the filing status of the required Registration Statement within the 30-day window.